The Chinese Early-onset Hypertension Study (CHESS)
CHESS
1 other identifier
observational
5,000
1 country
1
Brief Summary
Hypertension (HTN) is the most important cardiovascular risk factor which is responsible for 50% of cardiovascular morbidity and mortality, and also a substantial public health problem affecting approximately 1/4 of the adult population in industrialized societies and over 1 billion people worldwide. Chronically elevated blood pressure without well control puts people at increased risk of target organ damages, including stroke, myocardial infarction, congestive heart failure, end-stage renal disease, blindness, and death. Especially, these damages are dramatically more severe in the early-onset hypertensive population.
Trial Health
Trial Health Score
Automated assessment based on enrollment pace, timeline, and geographic reach
participants targeted
Target at P75+ for all trials
Started Oct 2012
Longer than P75 for all trials
1 active site
Health score is calculated from publicly available data and should be used for screening purposes only.
Trial Relationships
Click on a node to explore related trials.
Study Timeline
Key milestones and dates
Study Start
First participant enrolled
October 1, 2012
CompletedFirst Submitted
Initial submission to the registry
May 20, 2016
CompletedFirst Posted
Study publicly available on registry
June 30, 2016
CompletedPrimary Completion
Last participant's last visit for primary outcome
December 1, 2020
CompletedStudy Completion
Last participant's last visit for all outcomes
December 1, 2020
CompletedJanuary 9, 2018
January 1, 2018
8.2 years
May 20, 2016
January 7, 2018
Conditions
Keywords
Outcome Measures
Primary Outcomes (1)
primary mortality of early-onset hypertension
the primary mortality of early-onset hypertension
through study completion, an average of 5 years
Secondary Outcomes (4)
secondary outcomes of heart
through study completion, an average of 5 years
secondary outcomes of brain
through study completion, an average of 5 years
secondary outcomes of kidney
through study completion, an average of 5 years
secondary outcomes of eyes
through study completion, an average of 5 years
Study Arms (1)
early-onset hypertension
early-onset hypertension patients recruited in Chinese multiple centers
Eligibility Criteria
Between October 2012 and December 2020(anticipated) recruited from multiple centers in China, in accordance with the diagnosis of hypertension, and less than 40 years when diagnosed
You may qualify if:
- In accordance with the diagnosis of hypertension (BP≥140/90mmHg), and less than 40 years when diagnosed
Contact the study team to confirm eligibility.
Sponsors & Collaborators
Study Sites (1)
Fuwai hospital
Beijing, Beijing Municipality, 100037, China
Biospecimen
Blood samples are collected after 12-hour overnight fast and biological variables are determined. Genomic DNA is isolated from leukocytes according to a standard procedure.
MeSH Terms
Conditions
Condition Hierarchy (Ancestors)
Study Officials
- PRINCIPAL INVESTIGATOR
Lei Song, MD.& PhD.
Chinese Academy of Medical Sciences, Fuwai Hospital
Central Study Contacts
Study Design
- Study Type
- observational
- Observational Model
- COHORT
- Time Perspective
- PROSPECTIVE
- Sponsor Type
- OTHER GOV
- Responsible Party
- PRINCIPAL INVESTIGATOR
- PI Title
- MD, ph.D
Study Record Dates
First Submitted
May 20, 2016
First Posted
June 30, 2016
Study Start
October 1, 2012
Primary Completion
December 1, 2020
Study Completion
December 1, 2020
Last Updated
January 9, 2018
Record last verified: 2018-01